Content Type:Research | 25 April 2019International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)Authors:Jan Beyer-Westendorf, A. John Camm, Keith A. A. Fox, Jean-Yves Le Heuzey, Sylvia Haas, Alexander G. G. Turpie, Saverio Virdone and Ajay K. Kakkar
Content Type:Review | 15 April 2019Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically illAuthors:Benjamin Brenner, Russell Hull, Roopen Arya, Jan Beyer-Westendorf, James Douketis, Ismail Elalamy, Davide Imberti and Zhenguo Zhai
Content Type:Review | 29 March 2019Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseasesAuthors:Dorothea M. Heuberger and Reto A. Schuepbach
Content Type:Research | 15 February 2019Sensory evaluation of edoxaban orally disintegrating tablets: an open-label interventional study (secondary publication)Authors:Takeshi Yamashita, Joji Hagii, Yoshiyuki Morishima, Takaaki Akasaka, Takuyuki Matsumoto and Tetsuya Kimura
Content Type:Review | 25 January 2019Predictive risk factors of venous thromboembolism (VTE) associated with peripherally inserted central catheters (PICC) in ambulant solid cancer patients: retrospective single Centre cohort studyAuthors:Osamah Al-Asadi, Manar Almusarhed and Hany Eldeeb
No comments:
Post a Comment